Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
Bruker Corporation BRKR recently introduced the D6 PHASER X-Ray Diffraction (“XRD”) system. The new benchtop XRD platform is designed with the analytical flexibility typically available only in larger, floor-standing systems.
The newest offering is built on the success of the Bruker D2 PHASER XRD system. The D6 PHASER benchtop XRD platform will support material analysis and advanced material discoveries by offering unmatched benchtop capabilities, versatility and a great user experience.
News in Detail
In contrast to conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. It combines the functionality of the floor-standing D8 platform with an innovative benchtop design that includes high X-ray excitation power and a versatile set of X-ray optics. The Motorized Air Scatter Screen enables dynamic beam optimization for optimum performance over the goniometer range.
Image Source: Zacks Investment Research
The D6 PHASER can be equipped with a range of sample stages for a large variety of X-ray diffraction applications, including capillary transmission, grazing incidence diffraction, X-ray reflectometry, residual stress, texture analysis and non-ambient investigations. The DaVinci stage interface allows swapping sample stages without realignment.
Combined with the DIFFRAC.SUITE software, the D6 PHASER provides flexibility for automated push-button methods or to customize measurement configurations for optimized data quality. The system does not require any external water cooling and has no special electrical requirements for convenience to bring versatile, high-performance XRD to any laboratory.
The D6 PHASER is available as a GxP-compliant solution and complies with the latest radiation protection and machinery directives. With its wide range of capabilities, the platform will enable more XRD applications for new markets and user communities.
Industry Prospects
Per a Research report, the global XRD market was valued at $690.1 million in 2019 and is expected to witness a CAGR of 3.2% by 2026.
Recent Highlights
At the 71st ASMS meeting held from Jun 4-8, 2023, BRKR announced transformative sensitivity on the 4D-Proteomics timsTOF platform with the launch of the timsTOF Ultra mass spectrometer. The company also introduced the VistaScan software for enhanced dia-PASEF 4D-Proteomics, the EVOQ DART-TQ+ mass spectrometer, the Impact II VIP ESI-TOF (time of flight) system and the TargetScreener 4D software for applied markets.
Earlier in May, Bruker completed the acquisition of ZONTAL Inc. The buyout strengthens Bruker BioSpin’s Integrated Data Solutions software division, which includes Mestrelab Research, Arxspan and Optimal.
Price Performance
In the past six months, Bruker has outperformed the industry. Shares of the company have rallied 10.1% against the industry’s fall of 11.7%.
Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Penumbra PEN, Lantheus LNTH and Rockwell Medical RMTI. While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Rockwell Medical carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has surged 154.6% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 32.4% in the past year against the industry’s 22.6% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Rockwell Medical’s loss per share have narrowed from 58 cents to 48 cents for 2023 in the past 30 days. Shares of the company have surged 211.8% in the past year against the industry’s 22.5% decline.
RMTI’s earnings beat estimates in three of the trailing four quarters, the average surprise being 30.4%. In the last reported quarter, Rockwell Medical delivered an earnings surprise of 44.4%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bruker Corporation (BRKR) : Free Stock Analysis Report
Rockwell Medical, Inc. (RMTI) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
